🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Platinum-sensitive

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy NCT07504588Phase 213 sites📍 Fayetteville📍 Rogers📍 Springdale National Cancer Institute (NCI) · Tests: Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) NCT03983226Phase 25 sites📍 Shanghai📍 Guangzhou📍 Hangzhou Shanghai Gynecologic Oncology Group · Tests: Surgery, carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin..., Nirap… Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). NCT06663098Phase 225 sites📍 Aviano (PN)📍 Bari📍 Bologna Gruppo Oncologico Italiano di Ricerca Clinica · Tests: Atezolizumab, Carboplatin, Etoposide Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer NCT05080556Phase 21 site📍 London University College, London · Tests: Carboplatin Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer NCT07171528Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Secondary Cytoreductive Surgery An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib NCT05887609Phase 26 sites📍 Irvine📍 Aurora📍 Chicago University of Colorado, Denver · Tests: Mirvetuximab Soravtansine-gynx, Olaparib Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer NCT06040970Phase 1, Phase 21 site📍 New York Icahn School of Medicine at Mount Sinai · Tests: Sacituzumab, Cisplatin Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi NCT05551208Phase 21 site📍 Chongqing Chongqing University Cancer Hospital · Tests: fluzopanib and bevacizumab A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors NCT05914116Phase 1, Phase 2107 sites📍 Tucson📍 Los Angeles📍 Los Angeles DualityBio Inc. · Tests: DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance NCT07321015Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Fluzoparib Monotherapy A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) NCT07743164Phase 34 sites📍 Fountain Valley📍 Orlando📍 Tel Aviv Merck Sharp & Dohme LLC · Tests: R-DXd, Bevacizumab, Carboplatin, Paclitaxel, Gemcitabine Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002Phase 1, Phase 21 site📍 Wuhan Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1811, Carboplatin, Bevacizumab, Oxaliplatin for Injection, Paclitaxel injection Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer NCT04519151Phase 21 site📍 Ramat Gan Sheba Medical Center · Tests: Pembrolizumab, Lenvatinib A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) NCT06824467Phase 3198 sites📍 Birmingham📍 Anchorage📍 Irvine Merck Sharp & Dohme LLC · Tests: Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent) Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer NCT06467786Phase 41 site📍 Xi'an Tang-Du Hospital · Tests: Irinotecan hydrochloride liposome injection Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer NCT07816666Phase 3124 sites📍 Anchorage📍 Miami📍 Indianapolis AstraZeneca · Tests: Torvutatug samrotecan, Bevacizumab Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer NCT05284539Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma NCT04678362Phase 214 sites📍 Angers📍 Besançon📍 Caen Centre Francois Baclesse · Tests: Talazoparib + Avelumab Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer NCT07564141Phase 39 sites📍 Duarte📍 Danbury📍 Tigard Genmab · Tests: Rina-S, Bevacizumab, Carboplatin, Gemcitabine, Paclitaxel Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy NCT07225270Phase 334 sites📍 Miami📍 Sarasota📍 Towson Genmab · Tests: Rina-S, Bevacizumab Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study. NCT06614790n/a12 sites📍 Bialystok📍 Gdansk📍 Gliwice Pomeranian Medical University Szczecin · Tests: Niraparib 200/300 MG CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer NCT05942300Phase 11 site📍 Pittsburgh Lan Coffman · Tests: CPI-0209, carboplatin Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer NCT06292286NA1 site📍 Hong Kong The University of Hong Kong · Tests: Carboplatin or cisplatin, Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar, B… RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression NCT06420973Phase 21 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: RC48+carboplatin±bevacizumab A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) NCT07684612Phase 39 sites📍 Newcastle📍 Toronto📍 Montreal GlaxoSmithKline · Tests: Mocertatug rezetecan (Mo-Rez), Carboplatin, Paclitaxel, Gemcitabine, Pegylated liposomal doxorubicin (PLD) Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer NCT06686030Phase 21 site📍 Wuhan Akeso · Tests: AK112 low dose, Chemotherapy, Olaparib, AK112 high dose A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies NCT07024784Phase 221 sites📍 Los Angeles📍 Aurora📍 Minneapolis AbbVie · Tests: IMGN151, Carboplatin, Bevacizumab, Olaparib Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer NCT05231122Phase 22 sites📍 Buffalo📍 Houston Roswell Park Cancer Institute · Tests: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire A… A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer NCT07213804Phase 3265 sites📍 Birmingham📍 Phoenix📍 Burbank Eli Lilly and Company · Tests: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy